Education
About Us
Working with TipRanks
Follow Us
Ceribell, Inc. (CBLL)
NASDAQ:CBLL
Top Page
Ceribell, Inc.
(NASDAQ:CBLL)
56Neutral
Positive Factors
Earnings
Ceribell reported Q4/24 revenue of $18.5M, beating both the estimate and consensus.
Market Expansion
Management will be focused on expanding its commercial organization to reach new accounts while driving higher utilization among active users.
Revenue Guidance
Ceribell issued 2025 revenue guidance of $81-$85m, above the Street’s $81m.
Negative Factors
Market Competition
The focus on seizure management in the acute care setting represents an opportunity of 3 million patients annually and a total addressable market of $2 billion.
Regulatory Challenges
Ceribell plans to submit for delirium approval, which would complement its current seizure indication and leverage the same sales force.
Ceribell, Inc. (CBLL) vs. S&P 500 (SPY)
Market Cap
$673.25M
Dividend YieldN/A
Average Volume (3M)203.09K
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees281
SectorHealthcare
Sector Strength78
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding35,868,340
10 Day Avg. Volume127,420
30 Day Avg. Volume203,092
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$33.67Price Target Upside75.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Ceribell, Inc. Business Overview & Revenue Model
Company DescriptionCeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
How the Company Makes MoneyCeribell, Inc. generates revenue primarily through the sale and leasing of its Rapid Response EEG systems to hospitals and healthcare facilities. The company also earns income from providing related services such as training, maintenance, and support for its devices. Additionally, Ceribell may enter into strategic partnerships with medical institutions and research organizations to further expand its market reach and enhance product offerings, contributing to its revenue streams.
Ceribell, Inc. Financial Statement Overview
Summary
Ceribell, Inc. shows strong revenue growth but struggles with profitability and cash flow management. The company has improved its financial position with significant equity increases and low leverage, but operational inefficiencies and dependency on external financing pose risks.Income Statement
Ceribell, Inc. shows solid revenue growth of 44.7% from 2023 to 2024, highlighting strong demand for their products. However, the company is operating at a loss with a negative net profit margin, and EBIT and EBITDA margins indicate inefficiencies. Gross profit margins are strong at approximately 86.7% for 2024, signifying good production cost management but are overshadowed by the high operating expenses.45
Neutral
Balance Sheet
The company's equity has significantly improved from negative to a strong positive position in 2024, indicating strong financial backing or recent capital infusion. The debt-to-equity ratio is low due to high equity, showcasing low leverage risk. However, the equity ratio is high at 84.8%, reflecting a stable asset base primarily funded by equity.60
Neutral
Cash Flow
Ceribell's free cash flow is negative but has shown improvement from 2023. The high operating cash outflows are concerning, relative to the negative net income, indicating cash management issues. A significant financing cash flow in 2024 suggests reliance on external funding to cover operational deficits.50
Neutral
| Breakdown | ||
| Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|
| Income Statement | Total Revenue | |
| 65.44M | 45.23M | 25.92M | Gross Profit |
| 56.75M | 38.16M | 21.49M | EBIT |
| -39.71M | -30.04M | -36.02M | EBITDA |
| -37.71M | -26.51M | -35.06M | Net Income Common Stockholders |
| -40.45M | -29.46M | -37.16M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |
| 194.37M | 34.49M | 68.23M | Total Assets |
| 225.41M | 58.92M | 86.46M | Total Debt |
| 21.96M | 14.20M | 18.22M | Net Debt |
| -172.41M | -20.29M | -50.02M | Total Liabilities |
| 34.25M | 171.17M | 172.86M | Stockholders Equity |
| 191.16M | -112.25M | -86.40M |
| Cash Flow | Free Cash Flow | |
| -36.38M | -30.14M | -32.52M | Operating Cash Flow |
| -35.04M | -29.16M | -32.00M | Investing Cash Flow |
| -1.60M | -1.76M | -1.40M | Financing Cash Flow |
| 196.52M | -2.82M | 49.80M |
Ceribell, Inc. Risk Analysis
Ceribell, Inc. disclosed 79 risk factors in its most recent earnings report. Ceribell, Inc. reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ceribell, Inc. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.25B | ― | -33.30% | ― | 25.74% | 57.18% | |
56 Neutral | $2.12B | 34.40 | 4.87% | ― | 8.33% | 256.54% | |
56 Neutral | $673.25M | ― | 26.25% | ― | ― | ― | |
52 Neutral | $271.51M | ― | -25.76% | ― | -2.09% | -13.01% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
43 Neutral | $248.78M | ― | -139.60% | ― | 4.96% | -29.29% | |
43 Neutral | $1.87B | ― | -46.67% | ― | 18.82% | 19.76% |
* Healthcare Sector Average
Performance Comparison
CBLL
Ceribell, Inc.
18.73
-6.77
-26.55%
TNDM
Tandem Diabetes Care
17.66
-15.51
-46.76%
CYRX
CryoPort
5.44
-13.12
-70.69%
NVCR
NovoCure
16.98
2.69
18.82%
LIVN
LivaNova
37.48
-15.76
-29.60%
STIM
Neuronetics
3.60
-0.47
-11.55%
Ceribell, Inc. Earnings Call Summary
Earnings Call Date: Feb 25, 2025 | % Change Since: -24.67% | Next Earnings Date: Nov 18, 2025
Earnings Call Sentiment Positive
CeriBell demonstrated strong revenue growth and maintained high gross margins, successfully expanded its account base, and completed a successful IPO. However, increased operating expenses, a higher net loss, and tariffs on materials from China are notable challenges. Overall, the highlights outweigh the lowlights, indicating a positive sentiment for the earnings call.Highlights
Strong Revenue Growth
CeriBell reported Q4 2024 revenue of $18.5 million, reflecting 41% growth over the same period last year. For the full-year 2024, revenue totaled $65.4 million, representing 45% growth over 2023.
High Gross Margin
The company maintained a strong margin profile with a gross margin of 88% in Q4 and 87% for the full year.
Expansion of Active Accounts
CeriBell increased its active account set to 529 accounts by December 31, 2024, adding 25 new accounts in the quarter.
Successful IPO and Strong Cash Position
CeriBell completed a successful IPO in October, resulting in net proceeds of approximately $188 million, ending 2024 with $194.4 million in cash and cash equivalents.
Promising R&D Pipeline
CeriBell is expanding its R&D efforts, with plans to submit a 510(k) application for pediatric patients and developing algorithms for delirium detection, stroke detection, and other neurological conditions.
Lowlights
Increased Operating Expenses
Total operating expenses for Q4 2024 were $29.1 million, a 49% increase from Q4 2023, primarily due to investments in the commercial organization and costs associated with being a public company.
Net Loss Increase
CeriBell reported a net loss of $12.6 million for Q4 2024, compared to a loss of $8.3 million in Q4 2023. The full-year 2024 net loss was $40.5 million, up from $29.5 million in 2023.
Impact of Tariffs
The company faces a 35% tariff on materials sourced from China, up from 25% in 2024, impacting gross margins.
Company Guidance
During the CeriBell Q4 2024 earnings call, the company provided financial guidance for 2025, forecasting total revenue to range from $81 million to $85 million, reflecting an annual growth of 24% to 30% over 2024. For 2024, CeriBell reported a total revenue of $65.4 million, representing a 45% growth over 2023, with a Q4 revenue of $18.5 million marking a 41% increase from the previous year. The company maintained strong gross margins of 87% for the year and 88% for the quarter. As for operating expenses, 2024 saw an increase to $96.5 million, up 41% from the prior year, driven by investments in commercial expansion and transitioning to a public company. The net loss for 2024 was $40.5 million, or $3.39 per share, compared to a loss of $29.5 million in 2023. Looking forward, CeriBell plans to expand its sales team to 55 territory managers by mid-2025 and expects its gross margins to normalize in the mid to high 80% range despite increased tariffs on materials from China.Ceribell, Inc. Corporate Events
Executive/Board Changes
Ceribell, Inc. Announces Executive Compensation Adjustments
Neutral
Mar 14, 2025
On March 10, 2025, Ceribell, Inc. announced adjustments to the compensation packages of its top executives, effective April 1, 2025. The Board of Directors approved increases in the annual base salaries and target annual incentives for CEO Xingjuan (Jane) Chao, CFO Scott Blumberg, and CTO Raymond Woo, reflecting the company’s commitment to retaining key leadership.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.